• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G filed by Neoleukin Therapeutics Inc.

    2/14/24 4:16:35 PM ET
    $NLTX
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $NLTX alert in real time by email
    SC 13G 1 tm245429d33_sc13g.htm SC 13G

     

     

     

    UNITED STATES 

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    SCHEDULE 13G

     

    Under the Securities Exchange Act of 1934
    (Amendment No. )*

     

    Neurogene Inc.

    (Name of Issuer)

     

    Common Stock, par value $0.000001 per share

    (Title of Class of Securities)

     

    64135M 10 5

    (CUSIP Number)

     

    December 18, 2023

    (Date of Event Which Requires Filing of this Statement)

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

     

    ¨ Rule 13d-1(b)
    x Rule 13d-1(c)
    ¨ Rule 13d-1(d)

     

    *The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

     

    The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     

     

     

     

    CUSIP No. 64135M 10 5
     
      1.

    Names of Reporting Persons

    Samsara BioCapital, L.P.

     
      2. Check the Appropriate Box if a Member of a Group (See Instructions)
        (a) ¨
        (b) x (1)
     
      3. SEC Use Only
     
      4. Citizenship or Place of Organization
    Delaware
         
    Number of
    Shares
    Beneficially
    Owned by
    Each
    Reporting
    Person With
    5. Sole Voting Power
    0
     
    6. Shared Voting Power
     1,282,563 shares (2) 
     
    7. Sole Dispositive Power
     0
     
    8. Shared Dispositive Power
    1,282,563 shares (2)
     
      9. Aggregate Amount Beneficially Owned by Each Reporting Person
    1,282,563 shares (2)
     
      10. Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)  ¨
     
      11. Percent of Class Represented by Amount in Row (9)
    9.99% (3)
     
      12. Type of Reporting Person (See Instructions)
    PN
               

    (1)This Schedule 13G is filed by Samsara BioCapital, L.P. (“Samsara LP”), Samsara BioCapital GP, LLC (“Samsara GP”) and Dr. Srinivas Akkaraju (“Akkaraju”) (and together with Samsara LP and Samsara GP, the “Reporting Persons”). The Reporting Persons expressly disclaim status as a “group” for purposes of this Schedule 13G.

    (2)Consists of: (i) 1,267,790 shares of Common Stock held by Samsara LP; and (ii) 14,773 shares of Common Stock issuable upon exercise of pre-funded warrants (the “Warrants”) held by Samsara LP, by virute of a limitation on exercise of such warrants. Samsara GP is the sole general partner of Samsara LP and may be deemed to have voting and investment power over the securities held by Samsara LP. Akkaraju is a managing member of Samsara GP and may be deemed to have voting and dispositive power over the shares held by Samsara LP. The information with respect to the ownership of the Common Stock by the Reporting Persons filing this statement on Schedule 13G is provided as of December 31, 2023.

    (3)This percentage is calculated based on 12,823,696 shares of Common Stock outstanding as of December 18, 2023, as reported in the Issuer’s Current Report on Form 8-K, filed on December 19, 2023 with the Securities and Exchange Commission, plus the number of shares currently issuable upon exercise of the Warrants.

     

     

     

     

    CUSIP No. 64135M 10 5
     
      1.

    Names of Reporting Persons

    Samsara BioCapital GP, LLC

     
      2. Check the Appropriate Box if a Member of a Group (See Instructions)
        (a) ¨
        (b) x (1)
     
      3. SEC Use Only
     
      4. Citizenship or Place of Organization
    Delaware
         
    Number of
    Shares
    Beneficially
    Owned by
    Each
    Reporting
    Person With
    5. Sole Voting Power
    0
     
    6. Shared Voting Power
     1,282,563 shares (2)
     
    7. Sole Dispositive Power
     0
     
    8. Shared Dispositive Power
    1,282,563 shares (2)
     
      9. Aggregate Amount Beneficially Owned by Each Reporting Person
    1,282,563 shares (2)
     
      10. Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)  ¨
     
      11. Percent of Class Represented by Amount in Row (9)
    9.99% (3)
     
      12. Type of Reporting Person (See Instructions)
    OO
               

    (1)This Schedule 13G is filed by Samsara BioCapital, L.P. (“Samsara LP”), Samsara BioCapital GP, LLC (“Samsara GP”) and Dr. Srinivas Akkaraju (“Akkaraju”) (and together with Samsara LP and Samsara GP, the “Reporting Persons”). The Reporting Persons expressly disclaim status as a “group” for purposes of this Schedule 13G.

    (2)Consists of: (i) 1,267,790 shares of Common Stock held by Samsara LP; and (ii) 14,773 shares of Common Stock issuable upon exercise of pre-funded warrants (the “Warrants”) held by Samsara LP, by virute of a limitation on exercise of such warrants. Samsara GP is the sole general partner of Samsara LP and may be deemed to have voting and investment power over the securities held by Samsara LP. Akkaraju is a managing member of Samsara GP and may be deemed to have voting and dispositive power over the shares held by Samsara LP. The information with respect to the ownership of the Common Stock by the Reporting Persons filing this statement on Schedule 13G is provided as of December 31, 2023.

    (3)This percentage is calculated based on 12,823,696 shares of Common Stock outstanding as of December 18, 2023, as reported in the Issuer’s Current Report on Form 8-K, filed on December 19, 2023 with the Securities and Exchange Commission, plus the number of shares currently issuable upon exercise of the Warrants.

     

     

     

     

    CUSIP No. 64135M 10 5
     
      1. Names of Reporting Persons
    Dr. Srinivas Akkaraju
     
      2. Check the Appropriate Box if a Member of a Group (See Instructions)
        (a) ¨
        (b) x (1)
     
      3. SEC Use Only
     
      4. Citizenship or Place of Organization
    United States of America
         
    Number of
    Shares
    Beneficially
    Owned by
    Each
    Reporting
    Person With
    5. Sole Voting Power
    0
     
    6. Shared Voting Power
     1,282,563 shares (2)
     
    7. Sole Dispositive Power
     0
     
    8. Shared Dispositive Power
    1,282,563 shares (2)
     
      9. Aggregate Amount Beneficially Owned by Each Reporting Person
    1,282,563 shares (2)
     
      10. Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)  ¨
     
      11. Percent of Class Represented by Amount in Row (9)
    9.99% (3)
     
      12. Type of Reporting Person (See Instructions)
    IN
               

    (1)This Schedule 13G is filed by Samsara BioCapital, L.P. (“Samsara LP”), Samsara BioCapital GP, LLC (“Samsara GP”) and Dr. Srinivas Akkaraju (“Akkaraju”) (and together with Samsara LP and Samsara GP, the “Reporting Persons”). The Reporting Persons expressly disclaim status as a “group” for purposes of this Schedule 13G.

    (2)Consists of: (i) 1,267,790 shares of Common Stock held by Samsara LP; and (ii) 14,773 shares of Common Stock issuable upon exercise of pre-funded warrants (the “Warrants”) held by Samsara LP, by virute of a limitation on exercise of such warrants. Samsara GP is the sole general partner of Samsara LP and may be deemed to have voting and investment power over the securities held by Samsara LP. Akkaraju is a managing member of Samsara GP and may be deemed to have voting and dispositive power over the shares held by Samsara LP. The information with respect to the ownership of the Common Stock by the Reporting Persons filing this statement on Schedule 13G is provided as of December 31, 2023.

    (3)This percentage is calculated based on 12,823,696 shares of Common Stock outstanding as of December 18, 2023, as reported in the Issuer’s Current Report on Form 8-K, filed on December 19, 2023 with the Securities and Exchange Commission, plus the number of shares currently issuable upon exercise of the Warrants.

     

     

     

     

    Item 1.
      (a) Name of Issuer
    Neurogene Inc.
      (b)

    Address of Issuer’s Principal Executive Offices
    535 W 24th Street, 5th Floor

    New York, NY 10011

     
    Item 2.
      (a)

    Name of Person Filing
    Samsara BioCapital, L.P. (“Samsara LP”)

    Samsara BioCapital GP, LLC (“Samsara GP”)

    Srinivas Akkaraju (“Akkaraju”)

      (b)

    Address of Principal Business Office or, if none, Residence
    c/o Samsara BioCapital, LLC

    628 Middlefield Road

    Palo Alto, CA 94301

      (c) Citizenship      
        Entities: Samsara LP - Delaware
        Samsara GP - Delaware
        Individuals: Akkaraju - United States of America

      (d) Title of Class of Securities
    Common Stock, par value 0.000001 per share
      (e) CUSIP Number
    64135M 10 5
     
    Item 3. If this statement is filed pursuant to §§240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
      Not applicable.

     

    Item 4. Ownership
      The beneficial ownership information set forth below is provided as of December 31, 2023:

     

    Reporting Persons 

    Shares Held

    Directly

      

     

    Warrants Held Directly

      

    Sole

    Voting

    Power

      

    Shared

    Voting

    Power

      

    Sole

    Dispositive

    Power

      

    Shared

    Dispositive

    Power

      

    Beneficial

    Ownership

      

    Percentage

    of Class (3)

     
    Samsara LP (1) (2)   1,267,790    14,773    0    1,282,563    0    1,282,563    1,282,563    9.99%
    Samsara GP (1) (2)   0    0    0    1,282,563    0    1,282,563    1,282,563    9.99%
    Akkaraju (1) (2)   0    0    0    1,282,563    0    1,282,563    1,282,563    9.99%

     

    (1)Includes 1,267,790 shares of Common Stock held by Samsara LP and 14,773 shares issuable upon exercise of pre-funded warrants (the “Warrants”) held by Samsara LP. Pursuant to the terms of the Warrants, the Warrants are exercisable only to the extent that after giving effect to such exercise the holder thereof and their affiliates would beneficially own no more than 9.99% of outstanding common stock of the Issuer. Without giving effect to the above beneficial ownership limitation, the Warrants would be exercisable for an aggregate of 67,070 shares of Common Stock. Samsara LP may from time to time provide written notice to the Issuer to increase this limitation to any other percentage not in excess of 19.99%.

    (2)Samsara GP is the sole general partner of Samsara LP and may be deemed to have voting and investment power over the securities held by Samsara LP. Akkaraju is a managing member of Samsara GP and may be deemed to have voting and dispositive power over the shares held by Samsara LP.

    (3)This percentage is calculated based on 12,823,696 shares of Common Stock outstanding as of December 18, 2023, as reported in the Issuer’s Current Report on Form 8-K, filed on December 19, 2023 with the Securities and Exchange Commission, plus the number of shares currently issuable upon exercise of the Warrants.

     

     

     

     

    Item 5. Ownership of Five Percent or Less of a Class
      If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following   ¨.
       
    Item 6. Ownership of More than Five Percent on Behalf of Another Person
      Not applicable.
       
    Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company or Control Person
      Not applicable.
       
    Item 8. Identification and Classification of Members of the Group
      Not applicable.
       
    Item 9. Notice of Dissolution of Group
      Not applicable.
       
    Item 10. Certification
      By signing below, each of the undersigned certifies that, to the best of their knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under §240.14a-11.
       

     

     

     

     

    Signature

     

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     

    Dated: February 14, 2024

     

    Samsara BioCapital, L.P.   Samsara BioCapital GP, LLC
         
    By: Samsara BioCapital GP, LLC   By: /s/ Srinivas Akkaraju
    its General Partner     Name: Srinivas Akkaraju
          Title:   Managing Member
    By: /s/ Srinivas Akkaraju    
      Name: Srinivas Akkaraju    
      Title:   Managing Member    
         
      /s/ Srinivas Akkaraju    
      Srinivas Akkaraju    

     

      ATTENTION  
    Intentional misstatements or omissions of fact constitute Federal Criminal Violations (See 18 U.S.C. 1001).

     

     

    Get the next $NLTX alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $NLTX

    DatePrice TargetRatingAnalyst
    3/2/2022$30.00 → $25.00Overweight
    Piper Sandler
    8/6/2021$30.00Overweight
    Piper Sandler
    More analyst ratings

    $NLTX
    Financials

    Live finance-specific insights

    See more
    • Neurogene and Neoleukin Announce Definitive Merger Agreement

      Proposed merger to create Nasdaq-listed biotech company focused on advancing Neurogene's differentiated portfolio of genetic medicines for complex neurological diseases Combined company is expected to have a cash balance of approximately $200 million at close, including approximately $95 million from concurrent private financing by Neurogene's new and existing investors Cash expected to fund combined company into 2H:26 and through multiple catalysts, including preliminary data in 4Q:24 and additional data in 2H:25 from a Phase 1/2 clinical trial in Rett syndrome Companies to host conference call today at 8:30 am ET NEW YORK and SEATTLE, July 18, 2023 (GLOBE NEWSWIRE) -- Neurogene Inc.,

      7/18/23 6:30:00 AM ET
      $NLTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Neoleukin Therapeutics Announces Second Quarter 2022 Financial Results & Provides Corporate Update

      SEATTLE, Aug. 09, 2022 (GLOBE NEWSWIRE) -- Neoleukin Therapeutics, Inc., "Neoleukin" (NASDAQ:NLTX), a biopharmaceutical company utilizing sophisticated computational methods to design de novo protein therapeutics, today announced financial results for the second quarter ended June 30, 2022 and a midyear corporate update. "Our focus at Neoleukin is the advancement of de novo proteins to solve important therapeutic challenges and address unmet medical needs," said Jonathan Drachman, M.D., Chief Executive Officer of Neoleukin. "We are excited to be part of a revolutionary approach to creating therapeutic proteins that are not based on native sequences. Our first programs, including our lead

      8/9/22 4:02:00 PM ET
      $NLTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Neoleukin Therapeutics to Host Second Quarter 2022 Financial Results Conference Call and Webcast on August 9, 2022

      SEATTLE, July 27, 2022 (GLOBE NEWSWIRE) -- Neoleukin Therapeutics, Inc., "Neoleukin" (NASDAQ:NLTX), today announced it will report second quarter 2022 financial results on Tuesday, August 9, 2022 after the close of financial markets and then host a conference call and live audio webcast to discuss these results and provide a corporate update. Details of the event are as follows: Date: Tuesday, August 9, 2022 Time: 1:30 p.m. Pacific / 4:30 p.m. Eastern Toll-free: (800) 715-9871 Conference ID: 4116795 Webcast URL: http://investor.neoleukin.com/events The archived audio webcast will be available on the Investor Relations section of the Neoleukin website approximately two hours after the

      7/27/22 8:00:00 AM ET
      $NLTX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $NLTX
    Leadership Updates

    Live Leadership Updates

    See more
    • Neoleukin Therapeutics Provides Strategic Update and Announces Restructuring and Leadership Transition

      SEATTLE, March 08, 2023 (GLOBE NEWSWIRE) -- Neoleukin Therapeutics, Inc., "Neoleukin" (NASDAQ:NLTX), a biopharmaceutical company utilizing sophisticated computational methods to design de novo protein therapeutics, today announced that it has engaged SVB Securities to assist in reviewing strategic alternatives for the Company with the goal of maximizing shareholder value. Such alternatives may include a sale, merger, divestiture of assets, licensing or other strategic transaction. There can be no assurance that the exploration of strategic alternatives will result in any agreements or transactions, or that, if completed, any agreements or transactions will be successful or on attractive te

      3/8/23 5:00:00 PM ET
      $NLTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Neoleukin Therapeutics Announces First Quarter 2022 Financial Results and Corporate Update

      SEATTLE, May 09, 2022 (GLOBE NEWSWIRE) -- Neoleukin Therapeutics, Inc., "Neoleukin" (NASDAQ:NLTX), a biopharmaceutical company utilizing sophisticated computational methods to design de novo protein therapeutics, today announced financial results for the quarter ending March 31, 2022 and provided a corporate update. "During the first quarter of 2022 our dedicated team at Neoleukin has been focused on execution of our NL-201 Phase 1 clinical trial, evaluating multiple schedules during dose escalation in patients with relapsed and refractory solid tumors," said Jonathan Drachman, M.D., Chief Executive Officer of Neoleukin. "We anticipate reporting interim data from this trial during the sec

      5/9/22 4:05:00 PM ET
      $NLTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Neoleukin Therapeutics Announces Appointment of Donna Cochener as General Counsel

      SEATTLE, March 15, 2022 (GLOBE NEWSWIRE) -- Neoleukin Therapeutics, Inc., "Neoleukin" (NASDAQ:NLTX), a biopharmaceutical company utilizing sophisticated computational methods to design de novo protein therapeutics, today announced the appointment of Donna M. Cochener as General Counsel, Senior Vice President Legal. Ms. Cochener joins Neoleukin after serving as Senior Vice President, Deputy General Counsel at HomeStreet, Inc., the parent company of HomeStreet Bank. In that role, she was primarily responsible for securities reporting and compliance and corporate governance as well as serving as lead attorney on a range of transactions, including mergers and acquisitions and debt and equit

      3/15/22 8:00:00 AM ET
      $NLTX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $NLTX
    Press Releases

    Fastest customizable press release news feed in the world

    See more

    $NLTX
    SEC Filings

    See more
    • Neoleukin Therapeutics Announces 1-for-4 Reverse Stock Split

      SEATTLE, Dec. 14, 2023 (GLOBE NEWSWIRE) -- Neoleukin Therapeutics, Inc., "Neoleukin" or the "Company" (NASDAQ:NLTX), a biopharmaceutical company that has designed de novo protein therapeutics utilizing sophisticated computational methods, today announced that its Board of Directors ("Board") has approved a reverse stock split of the Company's outstanding shares of common stock at a ratio of 1-for-4. The reverse stock split will become effective at 12:02 a.m., Eastern Time on December 18, 2023. The Company's common stock is expected to begin trading on a post-reverse stock split basis on the Nasdaq Global Market on December 19, 2023, under the new name Neurogene Inc. and under the new symbo

      12/14/23 7:00:00 PM ET
      $NLTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Neoleukin Therapeutics Announces 1-for-5 Reverse Stock Split

      SEATTLE, Sept. 22, 2023 (GLOBE NEWSWIRE) -- Neoleukin Therapeutics, Inc., "Neoleukin" or the "Company" (NASDAQ:NLTX), a biopharmaceutical company that has designed de novo protein therapeutics utilizing sophisticated computational methods, today announced that its Board of Directors ("Board") has approved a reverse stock split of the Company's outstanding shares of common stock at a ratio of 1-for-5. The reverse stock split will become effective at 12:01 a.m. Eastern time on September 25, 2023. Neoleukin's common stock will begin trading on a post-reverse stock split basis on September 25, 2023, under Neoleukin's existing trading symbol "NLTX" with a new CUSIP number 64049K203. The reverse

      9/22/23 8:00:00 AM ET
      $NLTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Lifshitz Law PLLC Announces Investigations of HCCI, PRDS, NLTX, CCF

      NEW YORK, July 22, 2023 (GLOBE NEWSWIRE) -- Heritage-Crystal Clean, Inc. (NASDAQ:HCCI) Lifshitz Law PLLC announces an investigation into possible breach of fiduciary duties in connection with the sale of HCCI to an investment affiliate of J.F. Lehman & Company for $45.50 per share in cash for each share of HCCI common stock owned. If you are a HCCI investor, and would like additional information about our investigation, please complete the Information Request Form or contact Joshua Lifshitz, Esq. by telephone at (516)493-9780 or e-mail at [email protected]. Pardes Biosciences, Inc. (NASDAQ:PRDS) Lifshitz Law PLLC announces an investigation into possible breach of fiducia

      7/22/23 8:07:00 PM ET
      $CCF
      $HCCI
      $NLTX
      $PRDS
      Building Products
      Consumer Discretionary
      Miscellaneous
      Industrials
    • SEC Form 144 filed by Neoleukin Therapeutics Inc.

      144 - Neurogene Inc. (0001404644) (Subject)

      2/9/24 4:35:58 PM ET
      $NLTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Neoleukin Therapeutics Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits

      8-K - Neurogene Inc. (0001404644) (Filer)

      1/5/24 7:11:07 AM ET
      $NLTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Neoleukin Therapeutics Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders, Entry into a Material Definitive Agreement, Completion of Acquisition or Disposition of Assets, Financial Statements and Exhibits, Material Modification to Rights of Security Holders, Changes in Control of Registrant, Leadership Update, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Amendments to the Registrant's Code of Ethics, or Waiver of a Provision of the Code of Ethics, Shareholder Director Nominations, Regulation FD Disclosure

      8-K - Neurogene Inc. (0001404644) (Filer)

      12/19/23 7:31:02 AM ET
      $NLTX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $NLTX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Woods Robert Keith

      4 - Neurogene Inc. (0001404644) (Issuer)

      1/18/24 7:01:01 PM ET
      $NLTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Palekar Rohan

      4 - Neurogene Inc. (0001404644) (Issuer)

      1/18/24 6:58:27 PM ET
      $NLTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Noonberg Sarah B.

      4 - Neurogene Inc. (0001404644) (Issuer)

      1/18/24 6:56:12 PM ET
      $NLTX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $NLTX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G filed by Neoleukin Therapeutics Inc.

      SC 13G - Neurogene Inc. (0001404644) (Subject)

      2/14/24 6:05:00 PM ET
      $NLTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Neoleukin Therapeutics Inc. (Amendment)

      SC 13G/A - Neurogene Inc. (0001404644) (Subject)

      2/14/24 4:37:55 PM ET
      $NLTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Neoleukin Therapeutics Inc. (Amendment)

      SC 13G/A - Neurogene Inc. (0001404644) (Subject)

      2/14/24 4:26:22 PM ET
      $NLTX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $NLTX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Piper Sandler reiterated coverage on Neoleukin Therapeutics with a new price target

      Piper Sandler reiterated coverage of Neoleukin Therapeutics with a rating of Overweight and set a new price target of $25.00 from $30.00 previously

      3/2/22 8:41:36 AM ET
      $NLTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Piper Sandler resumed coverage on Neoleukin Therapeutics with a new price target

      Piper Sandler resumed coverage of Neoleukin Therapeutics with a rating of Overweight and set a new price target of $30.00

      8/6/21 7:21:14 AM ET
      $NLTX
      Biotechnology: Pharmaceutical Preparations
      Health Care